Protocole homéopathique d’accompagnement des inhibiteurs oraux des kinases dépendantes des cyclines 4 et 6 (CDK 4/6), dans le cancer du sein post-ménopausique métastatique hormonodépendant
La Revue d'Homéopathie, ISSN: 1878-9730, Vol: 10, Issue: 4, Page: 193-198
2019
- 2Citations
- 4Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Nouvelle classe thérapeutique, les inhibiteurs des kinases dépendantes des cyclines 4 et 6 sont indiqués dans le traitement des cancers du sein post-ménopausiques avancés, hormonodépendants et HER-2 négatifs. Assez bien tolérés sur le plan général, l’effet secondaire majeur est une neutropénie de grade 3 qui survient chez les deux-tiers des patientes, nécessitant la réduction, l’espacement, voire l’arrêt du traitement. L’étude du mécanisme physiopathologique de la toxicité hématopoïétique, la comparaison avec la matière médicale homéopathique et notre expérience clinique nous ont permis de dégager et de retenir un schéma thérapeutique homéopathique précis. L’association de Natrum muriaticum 7 CH, 3 granules le matin, Meduloss 8 DH, 15 gouttes le midi et Silicea 7 CH, 3 granules le soir, prescrits le plus tôt possible et durant toute la durée du traitement, permet de réduire l’intensité de la neutropénie et les infections concomitantes. L’ajout quotidien de l’hétéro-isothérapique de l’anti CDK 4/6 en 7 CH a parfois été nécessaire en cas de neutropénie persistante. Bien toléré par les patients et sans interférence médicamenteuse, ce protocole homéopathique est applicable par tout médecin. Dans notre expérience, le traitement de support homéopathique permet d’éviter l’espacement des cures, la réduction de la posologie et représente un gain de chances pour les patientes. Des études cliniques devront venir vérifier les résultats cliniques favorables obtenus. Cyclin-dependent kinase inhibitors 4 and 6 are a new therapeutic class and are indicated for the treatment of postmenopausal hormone-receptor-positive, HER-2-negative, advanced breast cancer. Generally well tolerated, the major side effect is grade 3 neutropenia, which occurs in two-thirds of patients, requiring reduction, spacing out, or even discontinuation of treatment. The study of the physio-pathological mechanism of hematopoietic toxicity, the comparison with homeopathic Materia Medica and our clinical experience enabled us to identify and retain a specific homeopathic therapeutic protocol. The combination of Natrum muriaticum 7c, 3 pills in the morning, Meduloss 8 DH, 15 drops in the afternoon and Silicea 7c, 3 pills in the evening, prescribed as soon as possible and for the whole duration of the treatment, makes it possible to reduce the intensity of neutropenia and concomitant infections. The daily addition of the hetero-isotherapic anti-CDK 4/6 in 7c has sometimes been necessary in cases of persistent neutropenia. Well tolerated by patients and without drug interference, this homeopathic protocol can be prescribed by any doctor. In our experience, homeopathic support treatment makes it possible to avoid the spacing out of sessions, the reduction of dosage, and so represents increased opportunities for the patients. Clinical studies will be needed to verify the favourable clinical results obtained.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1878973019301501; http://dx.doi.org/10.1016/j.revhom.2019.10.007; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85073822482&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S1878973019301501; https://dx.doi.org/10.1016/j.revhom.2019.10.007
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know